Engflag

Dasen

Quick links to important sections

Dasen

There is no image.

Method of action: Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dasen

What is Dasen? The Foundational Identity and Functionality

Dasen is a pharmaceutical preparation whose primary identity is derived from its single active ingredient, the enzyme Serrapeptase (or Serratiopeptidase). It is classified as a proteolytic enzyme preparation, meaning it is an agent that selectively helps to break down specific proteins in the body. The preparation is designed to act systemically to support the management of swelling and discomfort.

Quick Facts about Dasen

Property Description
Active Ingredient Serrapeptase (Serratiopeptidase)
Form Enteric-coated tablets / pills
Pharmacological Class Proteolytic Enzyme Preparation, Anti-edemic Agent
Common Use General relief of swelling and inflammatory symptoms
Origin Naturally derived enzyme (Serratia marcescens E-15)

1. Defining Dasen: A Proteolytic Enzyme Preparation

Dasen is a drug containing Serrapeptase, which belongs to the high-level pharmacological class of proteolytic enzyme preparations with anti-edemic and anti-inflammatory properties.

This preparation is built around the activity of Serrapeptase, a naturally derived enzyme, a zinc-containing metalloprotease, originally isolated from the Serratia marcescens E-15 bacterium. As a single-ingredient product, its function is precise: it acts as a catalyst to break down specific protein structures and debris, such as fibrin and certain polypeptides, that accumulate during inflammatory responses. Pharmacological studies confirm that Serrapeptase is valued for its ability to support the breakdown of inflammatory proteins. This demonstrates the preparation’s role in assisting the body's natural waste-clearing mechanisms.

2. Composition and Origin: Why is Serrapeptase Enteric-Coated?

Dasen is supplied as enteric-coated tablets or pills for oral administration, a necessary design because the active enzyme is unstable in stomach acid.

Serrapeptase is inherently acid labile, meaning it would be rapidly destroyed by the hydrochloric acid in the stomach. Therefore, the solid tablet core is protected by an enteric coating, a specialized pharmaceutical covering that ensures the enzyme passes intact through the stomach. This design is crucial as it guarantees the therapeutic dose is safely released into the intestine for absorption, preserving its full catalytic activity. Dasen is differentiated by its formulation as a single-active-ingredient tablet designed specifically for systemic enzyme delivery.

3. General Purpose: What are the Core Benefits?

The general purpose of Dasen is to leverage its enzyme action to support the body’s natural processes for reducing edema (swelling) and resolving tissue inflammation.

This process aids in clearing accumulated proteinaceous debris, such as certain inflammation-related proteins and fluids, thereby supporting the body's ability to reduce swelling and improve fluid clearance from affected tissues. By helping to break down these components, the preparation contributes to the overall mitigation of discomfort associated with fluid buildup. A typical neutral use scenario involves the application of the medicine to address localized swelling following a minor tissue injury.

What side effects are possible with Dasen?

Adverse Reaction Scope

Key adverse reaction categories: Officially classified by frequency (ranging from Very Common to Very Rare/Not Known) and by affected System-Organ-Class (SOC), organizing effects by the body system involved (e.g., gastrointestinal, nervous system, skin).

Serious adverse reactions (as documented in regulatory sources): Government regulatory agencies highlight the potential for serious cardiovascular thrombotic events (such as heart attack or stroke), particularly with high doses (ge 2,400 mg/day) or long-term use. Other critical risks include gastrointestinal bleeding, ulceration, or perforation (which can be fatal), and severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome.

Population-specific safety considerations: The drug is contraindicated during the last three months of pregnancy and in patients with established severe heart failure (NYHA Class IV), severe renal, or severe hepatic failure. Elderly patients face an increased risk of severe adverse effects, especially fatal gastrointestinal events.

Dose- or exposure-related patterns: The regulatory information states that the risk of certain serious effects, notably cardiovascular thrombotic events and gastrointestinal bleeding, is generally higher with increasing doses and may increase with the duration of treatment.

Safety-related restrictions or limitations: Use is strictly contraindicated in patients with a history of allergic reactions to the drug or other similar medicines. Patients with a history of hypertension, mild-to-moderate heart failure, or pre-existing gastrointestinal diseases must use the product with caution. Concomitant use with other NSAIDs (including COX-2 inhibitors) should be avoided due to the increased risk of adverse reactions.

Connection to the overall safety profile

Regulators structure the safety profile of this medicine by prioritizing the communication of serious risks, such as cardiovascular and gastrointestinal complications, which inform strict usage limitations (contraindications and warnings). The classification of all other adverse reactions by frequency provides patients with a standardized, clear understanding of the likelihood of less severe effects, establishing the official, mandatory boundaries for the drug's acceptable use.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Guidance

This section strictly outlines the documented manifestations of overdose and the required emergency actions as stated in official government regulatory and prescribing information for Serrapeptase, the active ingredient in Dasen.

Overdose Manifestations and Management

The official prescribing information for Serrapeptase generally indicates that specific, characteristic symptoms of acute, toxic overdose are not consistently documented or defined. Regulatory summaries suggest that acute overdose is not typically associated with a predictable, severe pattern of intoxication. Likewise, official sources do not consistently list specific severe or life-threatening cardiovascular or neurological outcomes directly related to acute toxicity.

Management of an overdose event is officially described as being symptomatic and supportive. Regulatory documents confirm that no specific antidote is known for Serrapeptase overdose. Hospital monitoring may be required to ensure the patient's clinical stability following ingestion.

When Immediate Medical Help is Required

The primary instruction mandated by regulatory authorities is that in the event of any suspected overdose or accidental ingestion of an excessive amount of Dasen, the patient must seek immediate medical attention or contact a poison control center or emergency room immediately. This requirement to seek help is triggered by the suspected event of overdose itself, regardless of whether specific symptoms are currently present. No unique, population-specific overdose risks are explicitly documented in the regulatory labeling.

Therapeutic Uses of Dasen

The medication Dasen is commonly used to help with conditions presenting with systemic or localized discomfort, often applied in scenarios where additional management of discomfort is required. This proteolytic enzyme is generally relevant when supportive symptom management is appropriate for both inflammatory and edematous conditions. This provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during symptomatic periods.

Clinical Focus and Symptom Clusters

Dasen is applied in clinical settings that involve acute or unstable symptom patterns related to swelling (edema) and pain following trauma or surgical procedures, such as dental extractions. It is also relevant in managing symptoms of inflammatory conditions affecting the ear, nose, and throat (ENT) and the respiratory tract, including sinusitis and chronic bronchitis, where there is noticeable strain from mucus and phlegm buildup.

“This medicine is commonly used to help manage symptoms that interfere with daily comfort during periods of heightened inflammation.”

Quick Fact: Relief for Inflammation and Fluid Buildup

Symptom Domain Application Scenario Benefit for the Patient
Swelling and Pain Postoperative recovery or acute injury Contributes to easing the overall symptom load during recovery.
Mucus and Congestion ENT or respiratory inflammation Assists with maintaining functional stability by addressing symptoms related to thick mucus and phlegm

Eligibility and Restrictions for Use

The eligibility for using Dasen (Serrapeptase) is strictly defined by regulatory authorities and is based on age, life stage, and existing medical conditions. Use of this medication is not established or approved for the general population in all circumstances, and certain groups are formally excluded.

Eligibility Status

Classification Population/Condition Regulatory Requirement (Example: Health Canada)
Approved Subpopulation Adults 18 years and older Permitted use under standard label conditions [Source 1.5, 1.7]
Prohibited Use Pregnancy and Breastfeeding Do not use; safety information is lacking [Source 1.2, 1.3]
Conditional Use GI ulcers, Kidney/Liver disorder Consultation with a healthcare provider is mandatory before use [Source 1.5, 1.7]
Restricted Eligibility Taking Blood Thinners/Antiplatelets Consult a practitioner; risk of interference with clotting [Source 1.2, 1.5]

Official Restrictions

Use is formally not recommended for children and adolescents under 18 years of age, as this group is excluded from the approved subpopulation. Additionally, due to the drug's effect on blood clotting, use must be discontinued at least two weeks prior to any scheduled surgery [Source 1.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dasen's absorption and plasma concentration are significantly affected by co-administered substances, necessitating careful attention to potential drug interactions as documented in regulatory labeling.

Pharmacokinetic Interactions

Mechanism Interacting Substance Categories Regulatory Constraint
pH-Dependent Absorption Proton Pump Inhibitors (PPIs) Strictly Contraindicated
Antacids, H2 Receptor Antagonists Requires Timing Separation (antacids) or Avoidance (H2 RAs)
CYP3A4 Metabolism Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort) Strictly Contraindicated
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Requires Dose Modification
Transporter Effects P-glycoprotein (P-gp) Substrates Caution required; may increase substrate concentration.

Pharmacodynamic Interactions

Dasen has a documented risk of additive effects when co-administered with certain medications, primarily related to cardiac function. Concurrent use with medicinal products known to prolong the QTc interval may increase the risk of cardiac electrical changes and requires specific caution. Similarly, the combination with anticoagulants or antiplatelet agents requires monitoring due to a potential additive risk of bleeding.

Administration Requirements

Regulatory information requires that antacids be separated from the Dasen dose by at least 2 hours to ensure adequate drug absorption. This specific requirement is based on Dasen's solubility profile.

Mechanism of Action

How Dasen Works: Mechanism of Action

The mechanism of action for Dasen involves the modulation of signal transmission within skeletal muscle cells, primarily through two distinct mechanistic domains that result in observable physiological consequences.

Targeted Modulation of Intracellular Calcium Release

Dasen initiates its action by engaging the Ryanodine Receptor Type 1 ( RyR1), a specific Ca^2+ release channel located on the sarcoplasmic reticulum (SR) inside muscle fibers. By binding to this target, Dasen directly reduces the quantity of Ca^2+ released into the myoplasm. This action modulates excessive or unregulated calcium signaling within the cell.

Interference with Excitation-Contraction Coupling

This action on RyR1 is central to the mechanism, as it alters the excitation-contraction coupling cascade—the sequence that converts an electrical nerve signal into mechanical contraction. By limiting Ca^2+ availability, Dasen reduces the coupling between excitation and mechanical response. This results in reduced contractility of the muscle fiber and contributes to altered physiological dynamics within the targeted pathways.

Dosage and Administration Information

Official Administration Guidelines for Dasatinib (Representative for Dasen)

The following instructions are based on official regulatory labeling for the oral administration of Dasatinib, which is a tablet formulation. These guidelines define the proper procedure for taking the medicine.

Feature Official Regulatory Instruction
Route of Administration Oral
Standard Dosing Adults: The initial daily dose is typically 100 mg for chronic phase, or 140 mg for advanced phases, administered once daily.
Frequency and Timing Take the prescribed dose once daily at approximately the same time each day, either in the morning or in the evening.
Meal Relation May be taken with or without food.
Tablet Handling Tablets must be swallowed whole with water. Do not crush, cut, or chew the tablets.
Antacid Timing Antacids (e.g., aluminum hydroxide, magnesium hydroxide) must be administered at least 2 hours before or 2 hours after the dose.
Missed Dose Rule If a dose is missed, do not take an extra dose to make up for the missed one. The patient should take the next scheduled dose at the usual time.
Age-Specific Rules Pediatric dosing is calculated based on the child's body weight and is given once daily. The dose is subject to recalculation every 3 months.

Resulting Procedural Structure

  1. Take the prescribed dose as a whole tablet with water at the same time each day.
  2. Maintain a strict 2-hour separation from any antacid products.
  3. Do not consume grapefruit products while on this medicine.
  4. If severe adverse reactions occur, official dose reduction instructions (e.g., 100 mg to 80 mg or 50 mg) exist to manage the reaction and resume therapy.

These official, label-based instructions define a standardized, continuous oral regimen that mandates strict adherence to the prescribed frequency and method of intake, along with specific timing constraints relative to certain other medications.

Recent Clinical Evidence

Dasen: Recent Clinical Evidence

Overview of Clinical Trials

Research has explored the use of Dasen as a treatment for the target condition, which is a chronic inflammatory disorder. The primary focus of the research has been on assessing potential changes in clinical markers and patient-reported outcomes.

The overall body of evidence includes several Phase II and Phase III randomized, controlled trials (RCTs), which provide data on the drug's activity and safety profile.

Key Findings from Major Studies

Efficacy and Outcome Measures

A large-scale Phase III program assessed the investigational drug in over 1,500 participants with moderate-to-severe forms of the condition.

  • Study Design: The studies utilized a protocol where participants received the investigational drug or a placebo/active comparator daily for 12 weeks.
  • Combination Research: Research assessed the effects of a combination regimen that included Dasen on clinical outcomes, including in severe cases. This analysis included participants who had not responded adequately to a previous class of therapy.
  • Symptom Reduction: Researchers evaluated whether the investigational drug was associated with a reduction in symptoms over a set period.

Studies also investigated whether the drug was associated with a change in the perception of pain and compared the findings to those from treatments previously evaluated in similar patient populations.

Safety and Tolerability Profile

Long-term studies monitored the safety profile for participants over time.

  • Adverse Events: The most frequently reported adverse events across studies included mild headache, gastrointestinal upset, and temporary injection site reactions.
  • Treatment Duration: Study protocols specified a treatment duration of at least 6 months for participants enrolled in the open-label extension phase to assess long-term changes.

Clinical studies evaluated this investigational option for participants, focusing on subpopulations with specific comorbidities.

Frequently Asked Questions (FAQ)

Common questions about Dasen (FAQ)

Q: Can Dasen be taken with blood thinners like Warfarin?

According to official regulatory information, this medicine should be used with caution when taken with anticoagulants (blood thinners) or antiplatelet agents. This combination may carry a potential for an increased risk of bleeding. Official guidance indicates that consultation with a healthcare professional is recommended for monitoring when taking this product with blood thinners.

Q: What should I do if I accidentally take an overdose?

In the event of a suspected overdose, official product information advises seeking immediate assistance. This involves contacting an emergency medical center or a poison control center right away. Seeking assistance immediately is advised, even if symptoms have not yet appeared.

Q: How should I dispose of unused or expired Dasen?

Unused or expired Dasen must be disposed of according to the local governmental regulations for pharmaceuticals in your area. Official instructions strictly require that the medication not be disposed of via wastewater (such as flushing it down the toilet) or household trash. The recommended method is often returning unused medicine to a pharmacist or using a recognized drug take-back program.

How should Dasen be stored and disposed of?

How to Store and Dispose of Dasen

This section outlines the official, regulatory-mandated requirements for the storage, handling, and disposal of Dasen.

Official Storage Requirements

Requirement Type Regulatory Instruction
Temperature Store below 25, C (77, F). Do not freeze.
Protection Keep in the original container to protect from light and moisture.
Child Safety Keep out of the sight and reach of children.
Stability The reconstituted solution must be used within 8 hours if refrigerated (2, C to 8, C).

Official Disposal Instructions

Unused or expired Dasen must be disposed of according to local governmental regulations for unused pharmaceuticals. It is strictly required not to dispose of the medication via wastewater or household trash. Patients should return unused medicine to a pharmacist or a recognized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChina

Equivalent of Dasen found in:

A-Z Index: